<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01638104</url>
  </required_header>
  <id_info>
    <org_study_id>ANX-042-C100</org_study_id>
    <nct_id>NCT01638104</nct_id>
  </id_info>
  <brief_title>ANX-042 Healthy Volunteer Dose Escalation Study</brief_title>
  <official_title>ANX-042 Healthy Volunteer Dose Escalation Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Anexon, Incorporated</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Celerion</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to investigate the safety and tolerability of ANX-042 when
      administered by continuous intravenous (IV) infusion in healthy volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Each participant received a total of two, approximately 12-hour continuous infusions of
      ANX-042 and one 12-hour continuous infusion of placebo, with a 36-hour washout period between
      treatments.

      This study was conducted by Anexon, Inc. at Celerion, in Lincoln, Nebraska.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2012</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with one or more drug-related adverse events (AEs) or any serious AEs</measure>
    <time_frame>0 to 4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area under the plasma concentration-time curve (AUC) of ANX-042</measure>
    <time_frame>0 to 24 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Steady state plasma concentration of ANX-042</measure>
    <time_frame>12 hours post dose</time_frame>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>ANX-042: 0.001 mcg/kg/min (with low sodium diet)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.001 dose unit equal to 1 millionth of a gram of an ANX-042 preparation / 1 kilogram of body mass administered / unit of time equal to 1 minute(mcg/kg/min), w/ diet restricted to 2.5 grams (gm) per day sodium (Na+) and 2.1 liters (L) fluid total daily intake</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ANX-042: 0.001 mcg/kg/min</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.001 mcg/kg/min ANX-042 with diet restricted to 4 gm per day Na+ and 3.6 L fluid total daily intake</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ANX-042: 0.003 mcg/kg/min (low sodium diet)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.003 mcg/kg/min ANX-042 with diet restricted to 2.5 gm per day Na+ and 2.1 L fluid total daily intake</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ANX-042: 0.003 mcg/kg/min</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.003 mcg/kg/min ANX-042 with diet restricted to 4 gm per day Na+ and 3.6 L fluid total daily intake</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ANX-042: 0.0065 mcg/kg/min (low sodium diet)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.0065 mcg/kg/min ANX-042 with diet restricted to 2.5 gm per day Na+ and 2.1 L fluid total daily intake</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ANX-042: 0.01 mcg/kg/min (low sodium diet)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.01 mcg/kg/min ANX-042 with diet restricted to 2.5 gm per day Na+ and 2.1 L fluid total daily intake</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ANX-042: 0.01 mcg/kg/min</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.01 mcg/kg/min ANX-042 with diet restricted to 4 gm per day Na+ and 3.6 L fluid total daily intake</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ANX-042: 0.03 mcg/kg/min</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.03 mcg/kg/min ANX-042 with diet restricted to 4 gm per day Na+ and 3.6 L fluid total daily intake</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ANX-042: 0.1 mcg/kg/min</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.1 mcg/kg/min ANX-042 with diet restricted to 4 gm per day Na+ and 3.6 L fluid total daily intake</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ANX-042: 0.3 mcg/kg/min</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.3 mcg/kg/min ANX-042 with diet restricted to 4 gm per day Na+ and 3.6 L fluid total daily intake</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (low sodium diet)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo and diet restricted to 2.5 gm per day Na+ and 2.1 L fluid total daily intake</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo and diet restricted to 4 gm per day Na+ and 3.6 L fluid total daily intake</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ANX-042</intervention_name>
    <description>Reconstituted in Sterile Water for Injection, United States Pharmacopeia (USP) and administered by 12 hour continuous intravenous infusion with 5% dextrose in water (D5W), United States Pharmacopeia (USP)</description>
    <arm_group_label>ANX-042: 0.001 mcg/kg/min (with low sodium diet)</arm_group_label>
    <arm_group_label>ANX-042: 0.001 mcg/kg/min</arm_group_label>
    <arm_group_label>ANX-042: 0.003 mcg/kg/min (low sodium diet)</arm_group_label>
    <arm_group_label>ANX-042: 0.003 mcg/kg/min</arm_group_label>
    <arm_group_label>ANX-042: 0.0065 mcg/kg/min (low sodium diet)</arm_group_label>
    <arm_group_label>ANX-042: 0.01 mcg/kg/min (low sodium diet)</arm_group_label>
    <arm_group_label>ANX-042: 0.01 mcg/kg/min</arm_group_label>
    <arm_group_label>ANX-042: 0.03 mcg/kg/min</arm_group_label>
    <arm_group_label>ANX-042: 0.1 mcg/kg/min</arm_group_label>
    <arm_group_label>ANX-042: 0.3 mcg/kg/min</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered once by 12 hour continuous intravenous infusion with D5W (USP)</description>
    <arm_group_label>Placebo (low sodium diet)</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women of non-reproductive potential (WNRP)

               -  Men must be willing to use effective contraception and not donate sperm for up to
                  90 days after the final dose of study drug

               -  Women must be of non-reproductive potential defined as a history of surgical
                  sterilization or postmenopausal status (that is, greater than ( &gt;) 50 years of
                  age with &gt;12 months amenorrhea while not using hormonal contraceptives or &gt;50
                  years of age with 6-12 months of amenorrhea and follicle stimulating hormone
                  (FSH) level &gt;40 international unit/liter (IU/L)

          -  Good health status, physically active without cardio-respiratory limitations and
             minimal concomitant medications as determined by medical history and physical
             examination

          -  Able and willing to comply with study procedures, including controlled sodium (Na)
             intake and restriction of caffeine and tobacco product

          -  Have given written informed consent prior to the initiation of any study procedures

        Exclusion Criteria:

          -  History of cardiovascular disease, unexplained syncope, postural tachycardia syndrome
             or frequent postural hypotension

          -  History or current evidence of respiratory, hepatic, renal, gastrointestinal,
             endocrine, hematological or neurological disorders that would constitute a risk when
             taking the study medication or interfere with the interpretation of data

          -  Clinically significantly abnormal clinical laboratory results (including Hepatitis B,
             Hepatitis C and Human Immunodeficiency Virus (HIV) serology) or physical examination
             results (confirmed by repeat measurement, if appropriate) that, in the opinion of the
             Investigator, would constitute a risk when taking the study medication or interfere
             with the interpretation of data

          -  Abnormal orthostatic Blood Pressure/Heart Rate (BP/HR) response at screening as
             defined by:

               -  Systolic Blood Pressure (BP) decrease &gt;20 millimeters of mercury (mmHg)

               -  Diastolic BP decrease &gt;10 mmHg, or

               -  HR increase &gt;25 beats per minute (bpm) and to a level above 100 bpm

          -  One or two supine values must be obtained between 8 and 10 minutes of supine rest. One
             or two upright values must be obtained between 3 and 5 minutes upright with the arm
             passively supported to maintain the brachial artery at heart level

          -  Abnormal 12-lead electrocardiogram (ECG) that interferes with proper measurement of
             QT-interval or, in the opinion of the Investigator, increases the risk of
             participating in the study

          -  Elevated BP (&gt;140/90 mmHg) in any posture, confirmed by repeat measurement

          -  Current use (within 7 days of first dosing) or expected need for concomitant
             medications with hemodynamic effects including: non-steroidal anti-inflammatory drugs
             (NSAIDS), decongestants, BP medications, diuretics, monoamine oxidase inhibitors,
             norepinephrine uptake inhibitors (for example, attention-deficit disorder medications,
             anti-depressants) and erectile dysfunction medications. Medications with low
             likelihood of hemodynamic or renal effects are permitted (for example, acetaminophen,
             vitamins, stable thyroid hormone, gastritis therapies, antihistamines, topical
             medications, et cetera) after approval by the Investigator

          -  Evidence of current or recent use of known drugs of abuse and/or positive findings on
             urinary drug screening

          -  History of an average weekly alcohol intake that exceeds 21 units per week (1 unit
             equal to (=) 12 ounces (oz) or 360 milliliters (mL) of beer; 5 oz or 150 mL of wine;
             1.5 oz or 45 mL of distilled spirits), or are unwilling to stop alcohol consumption
             for the duration of the study

          -  History of regular smoking of &gt;5 cigarettes, cigars and/or pipe bowls of tobacco per
             day

          -  Known allergies to nesiritide (Natrecor)

          -  History of blood donation of &gt;500 mL within one month, or plasma donation within 14
             days, of first dosing

          -  Are currently enrolled in, or have completed or discontinued within the last 30 days
             from, a clinical trial involving an investigational product or are concurrently
             enrolled in any other type of medical research judged not to be scientifically or
             medically compatible with this study

          -  Are investigator site personnel directly affiliated with this study or their immediate
             family members. Immediate family is defined as a spouse, parent, child or sibling,
             whether biological or legally adopted

          -  Are Lilly or Anexon employees or employees of any third-party organization (TPO)
             involved with the study that require exclusion of their employees
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email: Anexon@Choruspharma.com</last_name>
    <role>Study Director</role>
    <affiliation>Anexon, Incorporated</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Celerion</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 9, 2012</study_first_submitted>
  <study_first_submitted_qc>July 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2012</study_first_posted>
  <last_update_submitted>October 11, 2017</last_update_submitted>
  <last_update_submitted_qc>October 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Horng Chen</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

